⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALKS News
Alkermes Inc. plc
Alkermes to Report Second Quarter Financial Results on July 28, 2026
businesswire.com
ALKS
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
businesswire.com
ALKS
Form 8-K
sec.gov
ALKS
Drug-Delivery Technology Market Report 2026
globenewswire.com
MRK
ABBV
SNY
AZN
NVS
GSK
TEVA
REGN
VRTX
ALKS
HALO
Advancements in AUD Treatment: Precision Therapies and Future Growth Projections
globenewswire.com
ADIL
ALKS
LLY
ALT
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
businesswire.com
ALKS
Form 8-K
sec.gov
ALKS
Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
globenewswire.com
ALKS
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
businesswire.com
ALKS
Alkermes to Participate in the Goldman Sachs 47 th Annual Global Healthcare Conference
businesswire.com
ALKS